Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IL-4 fusion toxin effective in preclinical Kaposi's sarcoma models

July 2, 1999

Avax to launch M-Vax in Australia, forms joint venture for AC Vaccine

July 2, 1999

Transgene initiates phase I trial of malignant melanoma product

June 25, 1999

ImmunoGen receives second milestone payment for anticancer prodrug from SmithKline Beecham

June 22, 1999

Corixa teams up with Japan Tobacco on lung cancer vaccine research

June 21, 1999

Seven preclinical studies demonstrate antitumor activity of NovoMAb-G2

June 16, 1999

Campath-1H trial results presented in Barcelona

June 15, 1999

Follow-up data presented for Bexxar cancer therapy

June 15, 1999

Theragyn improves long-term survival in ovarian cancer patients

June 14, 1999

Data from phase I/II study of NBI-3001 presented at German Society of Neurosurgery

June 11, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...